EZH2 and synovial sarcoma: Here we show that tazemetostat (formerly known as EPZ-6438 or E7438), an early clinical-stage, selective and orally bioavailable small molecule inhibitor of EZH2 enzymatic activity induces anti-proliferative activity in preclinical models of synovial sarcoma, both as a single agent and in combination with chemotherapy.